Awesome!

The first molecule (Seattle Genetics' tucatinib) mentioned in this article were approved for Breakthrough Therapy Designation on Dec 18 2019.  On February 13 2020, Seattle Genetics said that the molecule has been accepted by the FDA for priority review of its New Drug Application!  Wow...that is stunningly fast!!!  Granted this is for breast cancer.

The other molecule (Novartis' capmatinib) was given Breakthrough Designation on Sept 6 2019 and has been accepted for priority review for its NDA on Feb 11 2020.  Lung cancer    

This FDA is moving at lightening speed!  If this is the new FDA, then priority review for Apabetalone is just a few months away...possibly.

Iconoclast